The estimated Net Worth of Mark Stejbach is at least $165 ezer dollars as of 26 May 2020. Mr. Stejbach owns over 2,051 units of Flexion Therapeutics Inc stock worth over $18,849 and over the last 13 years he sold FLXN stock worth over $0. In addition, he makes $146,184 as Independent Director at Flexion Therapeutics Inc.
Mark has made over 27 trades of the Flexion Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 2,051 units of FLXN stock worth $19,997 on 26 May 2020.
The largest trade he's ever made was exercising 18,000 units of Flexion Therapeutics Inc stock on 1 December 2015 worth over $311,400. On average, Mark trades about 3,492 units every 65 days since 2012. As of 26 May 2020 he still owns at least 2,051 units of Flexion Therapeutics Inc stock.
You can see the complete history of Mr. Stejbach stock trades at the bottom of the page.
Mark P. Stejbach serves as Independent Director of the Company. Mr. Stejbach joined our board of directors in 2016. Mr. Stejbach previously served as Senior Vice President and Chief Commercial Officer at Alkermes plc, a publicly traded global biopharmaceutical company, from 2012 to 2018. He currently serves as a senior commercial advisor to EIP Pharma LLC. Mr. Stejbach has over 30 years of experience in biotech and pharmaceuticals, including senior roles in a broad range of commercial functions including marketing, sales, economic affairs, managed care and finance. Prior to his role at Alkermes, Mr. Stejbach served as the Chief Commercial Officer at Tengion, Inc. from 2008 to 2012 and previously held senior positions at Merck and Biogen. Mark received his M.B.A. from the Wharton School, University of Pennsylvania and a B.S. in mathematics from Virginia Tech. Our Board believes that Mr. Stejbach’s executive and operational experience in the pharmaceutical industry and commercial expertise qualifies him to serve on our Board of Directors.
As the Independent Director of Flexion Therapeutics Inc, the total compensation of Mark Stejbach at Flexion Therapeutics Inc is $146,184. There are 9 executives at Flexion Therapeutics Inc getting paid more, with Michael Clayman having the highest compensation of $3,777,360.
Mark Stejbach is 57, he's been the Independent Director of Flexion Therapeutics Inc since 2016. There are 9 older and 6 younger executives at Flexion Therapeutics Inc. The oldest executive at Flexion Therapeutics Inc is Samuel Colella, 80, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON, MA, 01803.
Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon és Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.
Flexion Therapeutics Inc executives and other stock owners filed with the SEC include: